Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 13, 2013
Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndromeVictoria T Potter, Pramila Krishnamurthy, Linda D Barber, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 26, 2012
Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromesPramila Krishnamurthy, Victoria T Potter, Linda D Barber, et al.
Bone Marrow Transplantation|September 28, 2019
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)Jesus Feliu, Victoria Potter, Francesco Grimaldi, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
Frontiers in Transplantation|July 12, 2024
Systematic screening and focused evaluation for veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) following allogeneic stem cell transplant is associated with earlier diagnosis and prompt institution of defibrotide treatmentDaniele Avenoso, Michelle Kenyon, Varun Mehra, et al.
BMJ Open|January 8, 2025
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trialBenjamin H Mullish, Andrew J Innes, Lauren A Roberts, et al.
Transplantation and Cellular Therapy|August 14, 2023
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome PatientsDaniele Avenoso, Varun Mehra, Liron Barnea Slonim, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Leukemia|December 3, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective studyCarmelo Gurnari, Hideki Makishima, Arda Durmaz, et al.
Pageof 3